3 months Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus Zacks
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
XXENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
X